aminosteril n hepa 8%
fresenius kabi south africa (pty) ltd - combination multi-ingredient parenteral nutrition regimen (aminoacids) - infusion - combination multi-ingredient parenteral nutrition regimen (aminoacids)
aminosterile ke 10% i.v.infusion
fresenius kabi-scientific office - infusion - 10 %
easytouch alcohol prep pads nonsterile- isopropyl alcohol swab
mhc medical products, llc - isopropyl alcohol (unii: nd2m416302) (isopropyl alcohol - unii:nd2m416302) - antiseptic for preparation of the skin prior to injection
primest hand sanitizer nonsterile isopropy antiseptic- isopropyl alcohol gel
prime lab, llc - isopropyl alcohol (unii: nd2m416302) (isopropyl alcohol - unii:nd2m416302) - - health care personnel hand rub to reduce bacteria that potentially can cause disease.
essential hand sanitizer- isopropyl alcohol antiseptic 75% topical nonsterile solution solution
genesis custom chemical blending - isopropyl alcohol (unii: nd2m416302) (isopropyl alcohol - unii:nd2m416302) - antiseptic, hand sanitizer hand sanitizer to help reduce bacteria that potentially can cause disease. for use when soap and water are not available. - in children less than 2 months of age - on open skin wounds stop use and ask a doctor if irritation or rash occurs. these may be signs of a serious condition.
essential hand sanitizer- isopropyl alcohol antiseptic 75% topical nonsterile solution solution
genesis custom chemical blending - isopropyl alcohol (unii: nd2m416302) (isopropyl alcohol - unii:nd2m416302) - antiseptic, hand rub health care personnel hand rub to help reduce bacteria that potentially can cause disease. - in children less than 2 months of age - on open skin wounds stop use and ask a doctor if irritation or rash occurs. these may be signs of a serious condition.
nimotop 0.02% solution for infusion
bayer plc - nimodipine - solution for infusion or injection - nimodipine 0.02 % (w/v) - calcium channel blockers
oraltag- iohexol for solution
interpharma praha, a.s. - iohexol (unii: 4419t9mx03) (iohexol - unii:4419t9mx03) - iodine 4.5 g - oraltag is indicated for use in computed tomography of the abdomen and pelvis to opacify bowel loops and delineate between normal loops and adjacent organs or areas of suspected pathology. limitations of use oraltag is not indicated for diagnostic examination of the gastrointestinal tract. oraltag is contraindicated in patients with a known hypersensitivity to iodinated contrast agents, including iohexol [see warnings and precautions (5.2)] . risk summary there are no human data on risks associated with the use of oraltag during pregnancy. the background risk in the u.s. general population of major birth defects is 2% to 4% and risk of miscarriage is 15% to 20% of clinically recognized pregnancies. in animal reproduction studies, no evidence of fetal harm was observed with intravenous administration of iohexol to rats and rabbits at doses up to 100 times the maximum recommended human intravenous dose. risk summary iohexol administered intravenously is present in human
fluconazole 0.2% solution for i/v infusion
pharmatech cjsc - fluconazole - solution for i/v infusion - 2mg/ml
cipro hc- ciprofloxacin hydrochloride and hydrocortisone suspension
alcon laboratories, inc. - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u), hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - ciprofloxacin 2 mg in 1 ml - cipro® hc otic is indicated for the treatment of acute otitis externa in adult and pediatric patients, one year and older, due to susceptible strains of pseudomonas aeruginosa , staphylococcus aureus , and proteus mirabilis . cipro® hc otic is contraindicated in persons with a history of hypersensitivity to hydrocortisone, ciprofloxacin or any member of the quinolone class of antimicrobial agents. this nonsterile product should not be used if the tympanic membrane is known or suspected to be perforated. use of this product is contraindicated in viral infections of the external canal including varicella and herpes simplex infections. the safety and efficacy of cipro® hc otic have been established in pediatric patients 2 years and older (131 patients) in adequate and well-controlled clinical trials. efficacy has been extrapolated for patients, age 1 year and above based on studies in adults and older pediatric patients.